VEGF Inhibitors Disappoint in Adjuvant Renal Cell CarcinomaVEGF Inhibitors Disappoint in Adjuvant Renal Cell Carcinoma
Sorafenib and sunitinib do not prolong disease-free survival in patients with completely resected, locally advanced kidney cancer at high risk for recurrence. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Health | Hematology | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology